03260nam 2200625 a 450 991081266310332120230827225205.066128804571-282-88045-497866128804521-60750-609-2(CKB)2670000000047230(EBL)593778(SSID)ssj0000441330(PQKBManifestationID)12166145(PQKBTitleCode)TC0000441330(PQKBWorkID)10406820(PQKB)11659473(MiAaPQ)EBC593778(Au-PeEL)EBL593778(CaPaEBR)ebr10425042(CaONFJC)MIL288045(OCoLC)695394635(EXLCZ)99267000000004723020100721d2010 uy 0engur|n|---|||||txtccrPulmonary arterial hypertension[electronic resource] focusing on a future : enhancing and extending life /edited by J. Antel, M.B. Hesselink and R.T. SchermulyAmsterdam IOS Press20101 online resource (116 p.)Solvay Pharmaceuticals Conferences ;v. 10Description based upon print version of record.1-60750-601-7 Includes bibliographical references and index.Title page; Preface; List of Contributors; Contents; Conference Preface; Surgical Treatment of Pulmonary Arterial Hypertension; Pulmonary Arterial Hypertension Associated with Systemic Sclerosis: A Need for a More Focused Approach; Established and New Therapies for Hypoxia and Non-Hypoxia-Related Pulmonary Hypertension; Novel Anti-Proliferative Therapies in Pulmonary Hypertension; What Animal Models Tell Us About Treatments for Pulmonary Hypertension; Therapeutic Potential for Dual Inhibition of Endothelin Converting Enzyme and Neutral Endopeptidase in Pulmonary Arterial HypertensionPulmonary Vascular Disease in the Newborn - From Pathophysiology to Therapeutic StrategiesFrom Concept to Therapy - Alternative Route of Drug Application: Inhalation; Author IndexPulmonary hypertension is a fatal lung and heart disease. It is characterized by shortness of breath, fatigue and fainting. It is exacerbated by an increase of the pressure in the lung vasculature through exercise, leading to progressive worsening of hemodynamics, right ventricular hypertrophy, right heart insufficiency and finally right heart failure. This book focuses on pulmonary arterial hypertension, a rare and progressive subgroup of pulmonary hypertension, which is today incurable and terminally fatal. Classification of pulmonary arterial hypertension, its pathology, and strategies forSolvay Pharmaceuticals Conferences ;v. 10.Pulmonary hypertensionPulmonary hypertension.616.1616.1/32Antel J(Jochen)1712786Hesselink M. B1712787Schermuly R. T1712788MiAaPQMiAaPQMiAaPQBOOK9910812663103321Pulmonary arterial hypertension4105222UNINA